This invention is related to a method for producing polymer latex particle coated with silver nanoparticles. First, a polymer latex particle suspension is mixed with a silver nitrate solution in a weight ratio of 10:1 to 1:10 at 50 C. to 90 C. for 10 to 120 minutes to form a mixed solution. After the temperature of the mix solution is cooled to 50 C. to 85 C., a sodium citrate solution is added to react with the mixed solution for 10 to 240 minutes to form a polymer latex particle coated with silver nanoparticles, which has antibacterial activity.

The present disclosure is directed to compositions and methods for making a pharmaceutical composition by thermokinetic compounding, wherein the compositions include one or more thermolabile components, for example one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients. The methods comprise thermokinetic processing of the thermolabile components into a composite by blending certain thermolabile components in a thermokinetic mixer using multiple speeds during a single, rotationally continuous operation. The composite can be further processed into pharmaceutical compositions by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.

The present invention relates to a pediatric powder for reconstitution as suspension for oral administration comprising a therapeutically effective amount of an antiviral agent or pharmaceutical acceptable salt or derivative thereof, in particular Valaciclovir in complex with an ion exchange resin in a specific ratio in order to obtain a palatable and child-friendly product. It also relates to a process for the preparation thereof.

This invention is directed to compounds and salts that are generally useful as agents to treat an infection with Dirofilaria immitis. This invention also is directed to treatments comprising the administration of the compounds and salts to animals in need of the treatments.

A method to provide a therapeutic agent to an eye of a patient.

Pharmaceutical compositions and stable nano-suspensions comprising mifepristone and at least one pharmaceutically acceptable excipient, which exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. Manufacturing process and methods of use are also provided. The pharmaceutical compositions are used for prevention, treatment or prophylaxis of disorders in human patients in need thereof. Oral pharmaceutical compositions of mifepristone, methods for their administration, processes for their production, and use of these compositions are described for the treatment of diseases for which mifepristone is indicated.

This invention is related to a method for producing polymer latex particle coated with silver nanoparticles. First, a polymer latex particle suspension is mixed with a silver nitrate solution in a weight ratio of 10:1 to 1:10 at 50 C. to 90 C. for 10 to 120 minutes to form a mixed solution. After the temperature of the mix solution is cooled to 50 C. to 85 C., a sodium citrate solution is added to react with the mixed solution for 10 to 240 minutes to form a polymer latex particle coated with silver nanoparticles, which has antibacterial activity.

The present invention provides for compositions comprising a polymeric hydrogel impregnated with a toxin-absorbing or binding nanoparticle. The present invention also provides for the use of the above compositions for decreasing or neutralizing the effect of a toxin, or for treating or preventing an infection by a microbe that produces a toxin, in a subject. The exemplary toxin is a biological toxin such as a viral, bacterial, fungal, plant or animal toxin.

The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.

Stable crystalline forms of a compound represented by the formula (IA):

##STR00001##

an acid addition salt, and/or a solvate thereof are provided by the present invention. Said crystalline forms are extremely useful as materials for preparing medicines. Novel processes for preparing 6,7-unsaturated-7-carbamoyl morphinan derivatives are also provided by the present invention.